Abstract
Tumor targeting therapy, that is “Missile therapy”, using a complex composed of a tumor suppressive drug and a whole antibody against tumor cells, is expected to become an attractive chemotherapy strategy. However, clinically convincing results have not yet been obtained mainly due to poor transport from the circulation to tumor tissue and marked toxicity. Recently, recombinant immunotoxins, composed of an Fv fragment of an antibody to a tumor-related antigen fused to various truncated toxins have been developed to overcome the distribution of immunotoxins in tumors. These recombinant immunotoxins have shown encouraging clinical results for some hematopoietic malignancies. However, there were no significant anti-tumor responses to many tumors, especially solid tumors, probably due to their rapid clearance from the circulation and their immunogenicity and antigenicity. More recently, PEGylation of recombinant immunotoxins has been attempted to overcome these drawbacks. It was found that PEGylation of recombinant immunotoxins improves their effectiveness. We discuss the recent progress in tumor missile therapy. In contrast to others, we developed “Missile therapy against tumor blood vessels” by using specific monoclonal antibodies against tumor endothelial cells rather than actual tumor cells. The complex between antibodies to tumor vascular endothelial cells and anti-tumor drugs can freely access the target cells without concern for their vascular permeability. These preparations have exhibited excellent anti-tumor effects for solid tumors. In this review, we also discuss this vascular targeting therapy as an attractive new strategy for tumor chemotherapy.
Keywords: immunotoxin, pegylation, tumor vascular targeting, antibody, immunoconjugate, tumor necrosis factor-alpha, interleukin-6, tumor endothelial cells
Current Vascular Pharmacology
Title: Recent Progress on Tumor Missile Therapy and Tumor Vascular Targeting Therapy as a New Approach
Volume: 2 Issue: 3
Author(s): Yasuo Yoshioka, Yasuo Tsutsumi, Shinsaku Nakagawa and Tadanori Mayumi
Affiliation:
Keywords: immunotoxin, pegylation, tumor vascular targeting, antibody, immunoconjugate, tumor necrosis factor-alpha, interleukin-6, tumor endothelial cells
Abstract: Tumor targeting therapy, that is “Missile therapy”, using a complex composed of a tumor suppressive drug and a whole antibody against tumor cells, is expected to become an attractive chemotherapy strategy. However, clinically convincing results have not yet been obtained mainly due to poor transport from the circulation to tumor tissue and marked toxicity. Recently, recombinant immunotoxins, composed of an Fv fragment of an antibody to a tumor-related antigen fused to various truncated toxins have been developed to overcome the distribution of immunotoxins in tumors. These recombinant immunotoxins have shown encouraging clinical results for some hematopoietic malignancies. However, there were no significant anti-tumor responses to many tumors, especially solid tumors, probably due to their rapid clearance from the circulation and their immunogenicity and antigenicity. More recently, PEGylation of recombinant immunotoxins has been attempted to overcome these drawbacks. It was found that PEGylation of recombinant immunotoxins improves their effectiveness. We discuss the recent progress in tumor missile therapy. In contrast to others, we developed “Missile therapy against tumor blood vessels” by using specific monoclonal antibodies against tumor endothelial cells rather than actual tumor cells. The complex between antibodies to tumor vascular endothelial cells and anti-tumor drugs can freely access the target cells without concern for their vascular permeability. These preparations have exhibited excellent anti-tumor effects for solid tumors. In this review, we also discuss this vascular targeting therapy as an attractive new strategy for tumor chemotherapy.
Export Options
About this article
Cite this article as:
Yoshioka Yasuo, Tsutsumi Yasuo, Nakagawa Shinsaku and Mayumi Tadanori, Recent Progress on Tumor Missile Therapy and Tumor Vascular Targeting Therapy as a New Approach, Current Vascular Pharmacology 2004; 2 (3) . https://dx.doi.org/10.2174/1570161043385682
DOI https://dx.doi.org/10.2174/1570161043385682 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pyrazolo[4,3-<i>H</i>]quinazolines as Cyclin-dependent Kinase Inhibitors
for Treating Cancer
Current Medicinal Chemistry Receptor Tyrosine Kinase Kit and Gastrointestinal Stromal Tumours: An Overview
Current Medicinal Chemistry Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer
Current Cancer Drug Targets Highly Selective MEK Inhibitors
Current Enzyme Inhibition Development of Anticancer Agents from Plant-Derived Sesquiterpene Lactones
Current Medicinal Chemistry The Influence of Wuzhi Capsule on the Pharmacokinetics of Cyclophosphamide
Recent Patents on Anti-Cancer Drug Discovery Therapy Stratifications and Novel Approach in Pursuit of Aids Related Kaposi’s Sarcoma Management- A paradigm for Non Invasiveness
Current Drug Delivery Electrochemotherapy in the Treatment of Kaposi’s Sarcoma: A Single Centre Cohort Study and a Comparison with the Literature Data
Current Cosmetic Science Recent Applications of RNAi in Mammalian Systems
Current Pharmaceutical Biotechnology Planar Cell Polarity Signaling in Collective Cell Movements During Morphogenesis and Disease
Current Genomics High Mobility Group Box Protein-1 in HIV-1 Infection: Connecting Microbial Translocation, Cell Death and Immune Activation
Current HIV Research Dendritic Cells and their Receptors in Antitumor Immune Response
Current Molecular Medicine Denosumab: The Era of Targeted Therapies in Bone Metastatic Diseases
Current Cancer Drug Targets A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia
Current Medicinal Chemistry Cyclin-Dependent Kinase-2 as a Target for Cancer Therapy: Progress in the Development of CDK2 Inhibitors as Anti-Cancer Agents
Current Medicinal Chemistry Avian Cytokines - An Overview
Current Pharmaceutical Design Bioactive Natural Products from Endophytic Microbes
The Natural Products Journal Pharmacological Potentials and Nutritional Values of Tropical and Subtropical Fruits of India: Emphasis on their Anticancer Bioactive Components
Recent Patents on Anti-Cancer Drug Discovery PEDF as an Emerging Therapeutic Candidate for Osteosarcoma
Current Cancer Drug Targets Quinone-Based Drugs: An Important Class of Molecules in Medicinal Chemistry
Medicinal Chemistry